CRELUX GmbH

Company

    • Company type:
      • Research & Development
      • Service Provider
    • Year founded:
    • 2005
    • Employees (at the site):
    • 26
    • Turnover range:
    • <5m EUR
    • Products/services:
    • CRELUX is a global leader for structure based drug discovery solutions. Working for pharma, biotech and research organizations our products and services are highly individualized for our customers

      - 3 D structural analysis of target/compound complexes
      - Compound screening
      - Fragment screening
      - Recombinant proteins for assays, diagonstics and crystallization

    • Core competencies:
    • CRELUX provides fast and affordable access to co-crystal structures of your compounds in complex with their protein targets; Crystallization conditions of numerous relevant therapeutic targets have been established at CRELUX; Co-crystal structures of these targets in complex with your compounds of interest will be delivered at a fixed price with a typical turn around time of six to eight weeks; We do everything to protect your most important asset: compound IP.
      State-of the art proein production set-up to produce also challenging proteins in highest quality

    • Language skills:
    • English
      French
      German
      Spanish
    • Key Tech / section:
      • Biotechnology: Analytics and separation technology
    • Certification:
    • not available

    • Sales markets - target industries:
    • Pharmaindustrie Biotechnologie Chemische Industrie
    • Sales markets - target countries:
      • Belgium
      • Canada
      • Denmark
      • France
      • Germany
      • India
      • Italy
      • Japan
      • Spain
      • Sweden
      • Switzerland
      • United Kingdom
      • United States
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Martin Ried (Mr.)
      - Management

      Dr. Michael Schäffer (Mr.)
      - Management